High Potency Active Pharmaceutical Ingredients (HPAPI) Market

Q: What is the total market worth of high potency active pharmaceutical ingredients (HPAPI)?

The global market to reach US$ 36.83 Bn by 2027 Read More

High Potency Active Pharmaceutical Ingredients (HPAPI) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

According to Transparency Market Research’s latest report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market for the historical period 2017–2018 and forecast period 2019–2027, growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs are the factors likely to boost the growth of the market. However, containment of technical expertise in the hands of few major players and lack of universal regulatory policies and standards is poised to escalate the growth of the market.
According to the report, the global market was valued at US$ 17.45 Bn in 2018 and is anticipated to expand at a CAGR of over 8.7% from 2019 to 2027

high potency active pharmaceutical ingredients market

Growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs: Key Drivers of the Market

Pharmaceutical companies were skeptical in outsourcing manufacture of high potency APIs, and majority of the manufacturing was confined to captive or in-house. Major factor behind this was risk of patent infringement. However, as pharmaceutical companies started to expand geographical boundaries, they started experiencing shortage of HPAPIs. Furthermore, increasing cost of drug development and commercialization added to the financial burden. With developing regulatory and legal framework, outsourcing proved to be the most optimal option for HPAPI manufacturing.
Pharmaceutical companies can now focus on core business activities such as drug development and commercialization, while also take advantage of technical expertise at CMOs instead of investing in expensive HPAPI manufacturing setup.
Pharmaceutical companies have made significant investments in development of innovative drugs with targeted mode of action. Specific action and little or no side effects are major advantages for preference of such drugs. Various research articles published suggest that over 25% of the drugs in pipeline incorporate high potency active pharmaceutical ingredient (HPAPI). Currently only two antibody-drug conjugated drugs have been approved: Adcertis (Brentuximab vedotin) and Kadcyla (Trastuzumab emtansine). There are two other late stage candidates Inotuzumab ozogamicin (by, Pfizer) and IMMU-107 (by, Immunomedics). Several monoclonal antibody drugs are also expected to hit the High Potency Active Pharmaceutical Ingredients (HPAPI) Market in the near future. Palivizumab, ofatumumab, KW-0761, and pembrolizumab are only a few examples of monoclonal antibody drugs in phase 3.
With increasing number of potential phase 3 drug candidates, demand for contract manufacturing of HPAPIs has increased significantly in the recent past, and is one of the major drivers of the global HPAPI market.

Patent Expiry of Blockbuster Drugs Propel the Global Market Growth

Patent expiry and subsequent launch of generic versions is a lucrative opportunity for pharmaceutical companies to expand product portfolio and tap profitable market segments in this technology driven market. Various biosimilar have been approved in Europe, while the U.S. FDA has approved only one biosimilar to date. Increase in research and development activities and constant attempts toward mimicking branded biological drugs would pave the way for introduction of cost-effective treatment alternatives.
Various blockbuster drugs are expected to loose patent protection in the near future, providing large opportunities in the biosimilar market. Avastin (bevacizumab), Herceptin (trastuzumab), Synagis (palivizumab), Erbitux (cetuximab), Humira (adalimumab), Remicade (infliximab), and Rituxan (rituximab) are some of the major drugs going off patent in the near future.

Containment of Technical Expertise in the Hands of Few Major Players to Hamper the Market

High potency API manufacturing is capital intensive and requires skilled technical know-how; this has been a major barrier for new entrants who wish to tap the lucrative HPAPI market. Currently, few major players exist who have built their own capabilities through mergers, acquisitions, partnerships, and research and development.
Hence, the global HPAPI manufacturing market is leaning toward consolidation of expertise in the hands of few global players. Lonza, Novasep, SAFC, Cambrex, Teva API, Dr. Reddy’s Laboratories, and WuXi are key players in the HPAPI market.

Lack of Universal Regulatory Policies and Standards to Restrain the Market

The high potency API market is a rapidly growing market with large numbers of players looking to invest in building capabilities for manufacturing of HPAPIs. HPAPIs are highly toxic to human body. Hence, high level of care is taken during manufacturing of these compounds. Despite these complications, there does not exist any specific occupational health, safety, and environmental protection regulations that cover manufacturing of HPAPIs.
Private organizations such as Merck, Lonza, and SafeBridge have taken initiative to classify HPAPIs and (occupational exposure limits) OELs. However, CMOs need to maintain manufacturing standards as per client requirements due to lack of a universal guidelines. Introduction of universal guidelines and manufacturing policies would also provide credibility to CMOs, thus helping pharmaceutical companies in outsourcing business.

Competitive Landscape

This report profiles major players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) industry based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global market are
- Alkermes plc
- Cambrex Corporation
- Dr. Reddy's Laboratories
- Lonza Group
- Novasep
- Novartis AG
- Pfizer
- Sigma-Aldrich Co. LLC.
- WuXi AppTec
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Teva Pharmaceutical Industries
- Eli Lilly and Company
- Abbvie.

Key Developments

Key players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the market. A few expansion strategies adopted by players operating in the global market are:

In April 2019, U.S. based Cambrex Corporation expanded its new facility high-potency API production in U.S.
In 2018, FDA approved 59 drugs, of that 42 were small molecules and 17 were biologics which accounts to about 28.8% of total approvals which has risen from 26.1% from the year 2017. Few biologic drugs approved in 2018 are Trogarzo, Ilumya, Crysvita, Aimovig, Poteligeo, Emgality, Libtayo and Takyzyro.

The report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market discussed individual strategies, followed by company profiles of manufacturers of High Potency Active Pharmaceutical Ingredients. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the market

Frequently Asked Questions

What is the total market worth of high potency active pharmaceutical ingredients (HPAPI)?

The global market to reach US$ 36.83 Bn by 2027

What is the anticipated CAGR of the HPAPI market in the forecast period?

The market is anticipated to expand at a CAGR of over 8.7% from 2019 to 2027

What are the key driving factors for the growth of the high potency API market?

High potency API market is driven by growing preference for outsourcing of HPAPI manufacturing and patent expiry of blockbuster drugs

Which region is expected to project the highest market share in the global market?

North America accounted for a major share of the global market and the trend is anticipated to continue during the forecast period

Who are the key players in the market?

Key players in the global market include Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market

4. Market Overview

4.1. Introduction

4.1.1. Product Type/Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, 2017–2027

5. Key Insights

5.1. Value Chain Analysis

5.2. Event Impact analysis

5.3. Epidemiology of Cancer by Country/Sub-region

6. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by API Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

6.3.1. Synthetic

6.3.2. Biological

6.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Product Type

7. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Manufacture Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

7.3.1. Captive

7.3.2. Contract

7.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Manufacture Type

8. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Drug Type

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

8.3.1. Branded

8.3.2. Generic

8.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Drug Type

9. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Therapeutic Application

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

9.3.1. Oncology Drugs

9.3.2. Anti-diabetic Drugs

9.3.3. Cardiovascular Drugs

9.3.4. CNS Drugs

9.3.5. Musculoskeletal Drugs

9.3.6. Other Drugs

9.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Therapeutic Application

10. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Region

10.1. Key Findings

10.2. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Country/Region

11. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

11.2.1. Synthetic

11.2.2. Biological

11.3. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

11.3.1. Captive

11.3.2. Contract

11.4. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

11.4.1. Branded

11.4.2. Generic

11.5. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

11.5.1. Oncology Drugs

11.5.2. Anti-diabetic Drugs

11.5.3. Cardiovascular Drugs

11.5.4. CNS Drugs

11.5.5. Musculoskeletal Drugs

11.5.6. Other Drugs

11.6. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

11.6.1. U.S.

11.6.2. Canada

11.7. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis

11.7.1. By API Type

11.7.2. By Manufacture Type

11.7.3. By Drug Type

11.7.4. By Therapeutic Application

11.7.5. By Country

12. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

12.2.1. Synthetic

12.2.2. Biological

12.3. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

12.3.1. Captive

12.3.2. Contract

12.4. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

12.4.1. Branded

12.4.2. Generic

12.5. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

12.5.1. Oncology Drugs

12.5.2. Anti-diabetic Drugs

12.5.3. Cardiovascular Drugs

12.5.4. CNS Drugs

12.5.5. Musculoskeletal Drugs

12.5.6. Other Drugs

12.6. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

12.6.1. Germany

12.6.2. U.K.

12.6.3. France

12.6.4. Spain

12.6.5. Italy

12.6.6. Rest of Europe

12.7. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis

12.7.1. By API Type

12.7.2. By Manufacture Type

12.7.3. By Drug Type

12.7.4. By Therapeutic Application

12.7.5. By Country/Sub-region

13. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

13.2.1. Synthetic

13.2.2. Biological

13.3. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

13.3.1. Captive

13.3.2. Contract

13.4. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

13.4.1. Branded

13.4.2. Generic

13.5. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

13.5.1. Oncology Drugs

13.5.2. Anti-diabetic Drugs

13.5.3. Cardiovascular Drugs

13.5.4. CNS Drugs

13.5.5. Musculoskeletal Drugs

13.5.6. Other Drugs

13.6. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

13.6.1. China

13.6.2. Japan

13.6.3. India

13.6.4. Australia & New Zealand

13.6.5. Rest of Asia Pacific

13.7. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis

13.7.1. By API Type

13.7.2. By Manufacture Type

13.7.3. By Drug Type

13.7.4. By Therapeutic Application

13.7.5. By Country/Sub-region

14. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

14.2.1. Synthetic

14.2.2. Biological

14.3. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

14.3.1. Captive

14.3.2. Contract

14.4. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

14.4.1. Branded

14.4.2. Generic

14.5. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

14.5.1. Oncology Drugs

14.5.2. Anti-diabetic Drugs

14.5.3. Cardiovascular Drugs

14.5.4. CNS Drugs

14.5.5. Musculoskeletal Drugs

14.5.6. Other Drugs

14.6. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Rest of Latin America

14.7. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis

14.7.1. By API Type

14.7.2. By Manufacture Type

14.7.3. By Drug Type

14.7.4. By Therapeutic Application

14.7.5. By Country/Sub-region

15. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

15.1. Introduction

15.1.1. Key Findings

15.2. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

15.2.1. Synthetic

15.2.2. Biological

15.3. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

15.3.1. Captive

15.3.2. Contract

15.4. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

15.4.1. Branded

15.4.2. Generic

15.5. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

15.5.1. Oncology Drugs

15.5.2. Anti-diabetic Drugs

15.5.3. Cardiovascular Drugs

15.5.4. CNS Drugs

15.5.5. Musculoskeletal Drugs

15.5.6. Other Drugs

15.6. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Rest of Middle East & Africa

15.7. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis

15.7.1. By API Type

15.7.2. By Manufacture Type

15.7.3. By Drug Type

15.7.4. By Therapeutic Application

15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player – Competition Matrix (By Tier and Size of companies)

16.2. Market Share Analysis/Ranking By Company (2018)

16.3. Company Profiles

16.3.1. Alkermes plc,

16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.1.2. Growth Strategies

16.3.1.3. SWOT Analysis.

16.3.2. Cambrex Corporation

16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.2.2. Growth Strategies

16.3.2.3. SWOT Analysis.

16.3.3. Dr. Reddy's Laboratories

16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.3.2. Growth Strategies

16.3.3.3. SWOT Analysis.

16.3.4. Lonza Group

16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.4.2. Growth Strategies

16.3.4.3. SWOT Analysis.

16.3.5. Novasep

16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.5.2. Growth Strategies

16.3.5.3. SWOT Analysis.

16.3.6. Novartis AG

16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.6.2. Growth Strategies

16.3.6.3. SWOT Analysis.

16.3.7. Pfizer

16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.7.2. Growth Strategies

16.3.7.3. SWOT Analysis.

16.3.8. Sigma-Aldrich Co. LLC.

16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.8.2. Growth Strategies

16.3.8.3. SWOT Analysis.

16.3.9. WuXi AppTec

16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

16.3.9.2. Growth Strategies

16.3.9.3. SWOT Analysis.

List of Table

Table 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 07: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 08: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 09: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 10: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 11: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2027

Table 12: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 13: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 14: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 15: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 16: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 17: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 18: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 19: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 20: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 21: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 22: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 23: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 25: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 26: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 27: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 28: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 29: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 30: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 31: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

Table 32: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

Table 33: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

Table 34: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

Table 35: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 36: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figure

Figure 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Synthetic, 2017–2027

Figure 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Biological, 2017–2027

Figure 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 07: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 08: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Captive, 2017–2027

Figure 09: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Contract, 2017–2027

Figure 10: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 11: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 12: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oncology Drugs, 2017–2027

Figure 13: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-diabetic Drugs, 2017–2027

Figure 14: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cardiovascular Drug, 2017–2027

Figure 15: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CNS Drugs, 2017–2027

Figure 16: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Musculoskeletal Drugs, 2017–2027

Figure 17: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 18: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 19: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 20: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded, 2017–2027

Figure 21: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017–2027

Figure 22: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 23: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Region, 2018 and 2027

Figure 24: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Region, 2019–2027

Figure 25: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 26: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 27: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 28: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 29: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 30: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 31: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 32: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 33: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country, 2018 and 2027

Figure 34: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country, 2019–2027

Figure 35: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 36: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 37: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 38: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 39: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 40: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 41: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 42: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 43: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 44: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 45: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 46: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 47: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 48: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 49: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 50: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 51: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 52: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 53: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 54: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 55: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 56: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 57: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 58: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 59: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 60: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 61: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 62: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 63: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 64: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 65: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 66: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 67: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 68: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 69: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

Figure 70: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

Figure 71: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

Figure 72: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

Figure 73: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

Figure 74: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

Figure 75: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

Figure 76: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

Figure 77: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 78: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 79: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share, by Company, 2018